Oculis Holding AG (OCS)
NASDAQ: OCS · Real-Time Price · USD
27.91
-0.70 (-2.45%)
Mar 3, 2026, 2:20 PM EST - Market open
Oculis Holding AG Employees
Oculis Holding AG had 49 employees as of December 31, 2024. The number of employees increased by 13 or 36.11% compared to the previous year.
Employees
49
Change (1Y)
13
Growth (1Y)
36.11%
Revenue / Employee
$20,245
Profits / Employee
-$2,664,287
Market Cap
1.61B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 49 | 13 | 36.11% |
| Dec 31, 2023 | 36 | 8 | 28.57% |
| Dec 31, 2022 | 28 | - | - |
| Sep 30, 2022 | 32 | - | - |
| Jun 30, 2022 | 32 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Sarepta Therapeutics | 1,372 |
| Novavax | 952 |
| Nurix Therapeutics | 317 |
| Harmony Biosciences Holdings | 293 |
| Zymeworks | 263 |
| Innoviva | 127 |
| Kodiak Sciences | 123 |
| Definium Therapeutics | 74 |
OCS News
- 3 days ago - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - GlobeNewsWire
- 12 days ago - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated - GlobeNewsWire
- 14 days ago - Oculis Appoints Katie Kazem as Chief Legal Officer - GlobeNewsWire
- 6 weeks ago - Oculis Holding AG (OCS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 7 weeks ago - Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis - GlobeNewsWire
- 4 months ago - Oculis Reports Q3 2025 Financial Results and Provides Company Update - GlobeNewsWire
- 4 months ago - Oculis to Participate in Upcoming November Investor Conferences - GlobeNewsWire